- $17.40bn
- $21.32bn
- $9.68bn
- 91
- 90
- 41
- 87
Annual balance sheet for Biogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,610 | 3,803 | 4,893 | 1,050 | 2,375 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,327 | 1,962 | 2,136 | 2,100 | 1,869 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,887 | 7,857 | 9,791 | 6,859 | 7,457 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,845 | 3,792 | 3,703 | 3,730 | 3,538 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 24,619 | 23,877 | 24,554 | 26,845 | 28,049 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,742 | 4,298 | 3,273 | 3,434 | 5,529 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 13,919 | 12,981 | 11,156 | 12,045 | 11,333 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 10,700 | 10,896 | 13,398 | 14,799 | 16,716 |
Total Liabilities & Shareholders' Equity | 24,619 | 23,877 | 24,554 | 26,845 | 28,049 |
Total Common Shares Outstanding |